Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma

This is a multi-centric translational study with biological samples collection. The aim of this study is to validate a method to detect BRAFV600 in blood samples.

Samples: Blood from patients with BRAFV600 metastatic melanoma collected following standard medical practice.

The treatment is not the aim of the study. Patients can be treated either with specific or no-specific drug.

Inclusion Criteria:

• Confirmed diagnosis of melanoma and BRAFV600
• Signed Informed Consent Form
• Unresectable phase III or phase IV melanoma
• The patients should be starting a treatment for melanoma (either first line or subsequent lines)